Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(2 sites)
United States
Ohio State University Comprehensive Cancer Center, Columbus, Ohio University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania